The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

The "Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of Myopic Macular ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related ...

For those who smoke, this long-term habit can damage parts of your eye, contributing to serious conditions such as macular ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...